

IDL DIAGNOSTICS APPOINTS XIA JIANG AS DIRECTOR OF GLOBAL MARKET DEVELOPMENT

IDL Diagnostics AB (publ.) announces today that the company is strengthening its management team with the recruitment of Xia Jiang as Director of Global Market Development. Xia Jiang will have the responsibility for driving sales and establishing partnerships in new markets.

Xia Jiang has extensive international experience in the In Vitro Diagnostics (IVD) sector, managing key distribution channels across multiple regions including Asia-Pacific, Europe, Africa, and NGOs. She has a proven ability to establish and expand distribution networks in new markets, achieving significant revenue growth. Xia Jiang has a broad understanding of diverse healthcare systems, cultural environments, and distribution requirements.

Xia Jiang's most recent experience includes business development at Actim, part of the Medix Biochemica Group. Previously, Xia held key roles at Aidian and Optomed Oy, where she was based both in Finland and China.

"I am eager to begin working with IDL Diagnostics in this interesting phase that the company is in," says Xia Jiang "I look forward to leveraging my knowledge and experience to help drive the expansion of our global sales."

"I am delighted that Xia Jiang has chosen to join IDL Diagnostics," says Anders Hultman, CEO of IDL Diagnostics. "With Xia Jiang's extensive international background in sales and business development, she will play a pivotal role in expanding our presence in new markets. As IDL Diagnostics enters this phase of growth, bringing Xia Jiang on board significantly enhances our sales capabilities and our potential for success," concludes Anders Hultman.

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@idldiagnostics.com

About IDL Diagnostics

IDL Diagnostics AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. IDL Diagnostics' product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. IDL Diagnostics (IDLDX) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Attachments

IDL Diagnostics appoints Xia Jiang as Director of Global Market Development